Novo Nordisk A/S (NYSE:NVO) has earned a consensus recommendation of “Buy” from the fourteen research firms that are presently covering the company. Seven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $60.50.

Several brokerages have recently issued reports on NVO. HSBC reiterated a “hold” rating on shares of Novo Nordisk A/S in a research report on Thursday. Piper Jaffray Cos. started coverage on Novo Nordisk A/S in a research report on Friday, September 23rd. They set a “neutral” rating on the stock. Bank of America Corp. set a $57.00 target price on Novo Nordisk A/S and gave the stock a “hold” rating in a report on Saturday, September 17th. Jefferies Group restated a “hold” rating on shares of Novo Nordisk A/S in a report on Wednesday, September 14th. Finally, BNP Paribas upgraded Novo Nordisk A/S from a “neutral” rating to an “outperform” rating in a report on Tuesday, September 13th.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Jennison Associates LLC increased its position in shares of Novo Nordisk A/S by 16.4% in the second quarter. Jennison Associates LLC now owns 17,400,801 shares of the company’s stock worth $935,815,000 after buying an additional 2,452,120 shares in the last quarter. Loomis Sayles & Co. L P increased its position in shares of Novo Nordisk A/S by 6.3% in the second quarter. Loomis Sayles & Co. L P now owns 11,847,603 shares of the company’s stock worth $637,164,000 after buying an additional 705,851 shares in the last quarter. WCM Investment Management CA increased its position in shares of Novo Nordisk A/S by 5.4% in the second quarter. WCM Investment Management CA now owns 8,779,522 shares of the company’s stock worth $472,163,000 after buying an additional 450,232 shares in the last quarter. Folketrygdfondet increased its position in shares of Novo Nordisk A/S by 5.9% in the first quarter. Folketrygdfondet now owns 7,352,675 shares of the company’s stock worth $398,441,000 after buying an additional 407,387 shares in the last quarter. Finally, Fayez Sarofim & Co. increased its position in shares of Novo Nordisk A/S by 2.1% in the second quarter. Fayez Sarofim & Co. now owns 6,068,044 shares of the company’s stock worth $326,612,000 after buying an additional 126,829 shares in the last quarter. Institutional investors and hedge funds own 7.54% of the company’s stock.

Novo Nordisk A/S (NYSE:NVO) traded up 0.68% during trading on Thursday, reaching $39.85. The company had a trading volume of 3,959,256 shares. The firm has a market capitalization of $101.07 billion, a price-to-earnings ratio of 18.84 and a beta of 0.73. The stock has a 50 day moving average price of $44.42 and a 200 day moving average price of $51.60. Novo Nordisk A/S has a 12 month low of $39.03 and a 12 month high of $59.00.

About Novo Nordisk A/S

Novo Nordisk A/S is a healthcare company. The Company is engaged in discovery, development, manufacturing and marketing of pharmaceutical products. The Company’s business segments include diabetes and obesity care, and biopharmaceuticals. The diabetes and obesity care segment covers insulins, glucagon-like peptide-1 (GLP-1), other protein-related products (such as glucagon, protein-related delivery systems and needles), oral anti-diabetic drugs and obesity.

5 Day Chart for NYSE:NVO

Receive News & Stock Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related stocks with our FREE daily email newsletter.